Jump to main content
Jump to site search

Issue 5, 2007
Previous Article Next Article

Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors

Author affiliations

Abstract

Inhibitors of NAALADase have shown promise for a variety of diseases associated with glutamate excitotoxicity, and could be useful for the diagnosis and therapy of prostate cancer. A series of novel enantiomerically pure 2-(phosphonomethyl)pentanedioic acid (2-PMPA) based NAALADase inhibitors were synthesized. These compounds were prepared from previously reported (S)-2-(hydroxyphosphinoylmethyl)pentanedioic acid benzyl ester 4. Biological test results showed that the new compounds are good to outstanding NAALADase inhibitors. Compounds 8b and 10b showed activity similar to the known potent inhibitor (S)-2-PMPA. Fluorescently labeled inhibitor 19b may potentially be used to study binding to prostate cancer cells by fluorescence microscopy, and siderophore-containing inhibitor 21b may be useful for detection of prostate-derived cancer cells by magnetic resonance imaging (MRI).

Graphical abstract: Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors

Back to tab navigation

Publication details

The article was received on 27 Oct 2006, accepted on 13 Dec 2006 and first published on 19 Jan 2007


Article type: Paper
DOI: 10.1039/B615603G
Citation: Org. Biomol. Chem., 2007,5, 826-831
  •   Request permissions

    Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors

    P. Ding, P. Helquist and M. J. Miller, Org. Biomol. Chem., 2007, 5, 826
    DOI: 10.1039/B615603G

Search articles by author

Spotlight

Advertisements